Fernando Cabanillas

A predictive model for aggressive non-Hodgkin's lymphoma

Margaret A. Shipp, David P. Harrington, J R Anderson et al. · 1993 · 3.5K citations

Medicine, Oncology, Chemotherapy +15

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

Peter McLaughlin, A.J. Grillo-López, Brian K. Link et al. · Journal of Clinical Oncology · 1998 · 2.8K citations

Pharmacy, Hematology, Immunology +17

Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma

Thomas E. Witzig, Leo I. Gordon, Fernando Cabanillas et al. · Journal of Clinical Oncology · 2002 · 1.2K citations

Medicine, Immunology, Oncology +14

Non-Hodgkin's Lymphoma in 90 Homosexual Men

John L. Ziegler, Jay A. Beckstead, Paul A. Volberding et al. · New England Journal of Medicine · 1984 · 981 citations

Medicine, Hematology, Pathology +17

High-Dose Therapy and Autologous Bone Marrow Transplantation after Failure of Conventional Chemotherapy in Adults with Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma

Thierry Philip, Jamés O. Armitage, Gary Spitzer et al. · New England Journal of Medicine · 1987 · 781 citations

Medicine, Hematology, Oncology +17